Once-daily lamotrigine extended release for epilepsy management

References

• Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet367(9516), 1087–1100 (2006).
   PubMed Web of Science ®Google Scholar
• Mattson RH, Cramer JA, Collins JF. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Department of Veterans Affairs Epilepsy Cooperative Studies No. 118 and No. 264 Group. Neurology47(1), 68–76 (1996).
   PubMedGoogle Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med.342(5), 314–319 (2000).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav.3(4), 338–342 (2002).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA261(22), 3273–3277 (1989).
   PubMed Web of Science ®Google Scholar
• Bialer M. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications. Clin. Pharmacokinet.22(1), 11–21 (1992).
   PubMed Web of Science ®Google Scholar
• Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin. Ther.6(5), 592–599 (1984).
   PubMed Web of Science ®Google Scholar
• Bialer M. Extended-release formulations for the treatment of epilepsy. CNS Drugs21(9), 765–774 (2007).
   PubMed Web of Science ®Google Scholar
• Levy G. A pharmacokinetic perspective on medicament noncompliance. Clin. Pharmacol. Ther.54(3), 242–244 (1993).
   PubMed Web of Science ®Google Scholar
• Pellock JM, Smith MC, Cloyd JC, Uthman B, Wilder BJ. Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy. Epilepsy Behav.5(3), 301–307 (2004).
   PubMed Web of Science ®Google Scholar
• Goa KL, Ross SR, Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs46(1), 152–176 (1993).
   PubMed Web of Science ®Google Scholar
• Pellock JM. The clinical efficacy of lamotrigine as an antiepileptic drug. Neurology44(11 Suppl. 8), S29–S35 (1994).
   PubMedGoogle Scholar
• Dulac O, Kaminska A. Use of lamotrigine in Lennox–Gastaut and related epilepsy syndromes. J. Child Neurol.12(Suppl. 1), S23–S28 (1997).
   PubMedGoogle Scholar
• Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic–clonic seizures. Neurology65(11), 1737–1743 (2005).
   PubMed Web of Science ®Google Scholar
• Choi H, Morrell MJ. Review of lamotrigine and its clinical applications in epilepsy. Expert Opin. Pharmacother.4(2), 243–251 (2003).
   PubMed Web of Science ®Google Scholar
• Tompson DJ, Ali I, Oliver-Willwong R et al. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Epilepsia49(3), 410–417 (2008).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res.73(1), 1–52 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther.42(5), 535–541 (1987).
   PubMed Web of Science ®Google Scholar
• Magdalou J, Herber R, Bidault R, Siest G. In vitroN-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J. Pharmacol. Exp. Ther.260(3), 1166–1173 (1992).
   PubMed Web of Science ®Google Scholar
• Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine–valproic acid interaction. Drug Metab. Dispos.34(6), 1055–1062 (2006).
   PubMed Web of Science ®Google Scholar
• Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, Richens A. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res.1(3), 194–201 (1987).
   PubMed Web of Science ®Google Scholar
• Yuen AW, Land G, Weatherley BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. Br. J. Clin. Pharmacol.33(5), 511–513 (1992).
   PubMed Web of Science ®Google Scholar
• Morris RG, Black AB, Lam E, Westley IS. Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther. Drug Monit.22(6), 656–660 (2000).
   PubMed Web of Science ®Google Scholar
• Christensen J, Petrenaite V, Atterman J et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia48(3), 484–489 (2007).
   PubMed Web of Science ®Google Scholar
• Naritoku DK, Warnock CR, Messenheimer JA et al. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology69(16), 1610–1618 (2007).
   PubMed Web of Science ®Google Scholar
• Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia48(7), 1303–1307 (2007).
   PubMed Web of Science ®Google Scholar
• Matsuo F, Bergen D, Faught E et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology43(11), 2284–2291 (1993).
   PubMed Web of Science ®Google Scholar
• Messenheimer J, Ramsay RE, Willmore LJ et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia35(1), 113–121 (1994).
   PubMed Web of Science ®Google Scholar
• Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med.5(8), e166 (2008).
   PubMedGoogle Scholar
• Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf.18(4), 281–296 (1998).
   PubMed Web of Science ®Google Scholar